Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of ABT-126 in Mild-to-Moderate Alzheimer's Disease
NCT01690195Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Sep 2012
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of nelonicline in Alzheimer's disease (AD), sponsored by AbbVie Inc.. Started Sep 2012; status: terminated.
02
Drugs
nelonicline
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01690195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01690195.